Adalimumab for the Treatment of Non-Infectious Uveitis: A Real Life Experience

CONCLUSIONS: We consider adalimumab as a leading drug in the treatment of NIU with high safety and efficacy.PMID:38691840 | DOI:10.1080/09273948.2024.2344712

Source: Ocular Immunology and Inflammation - May 1, 2024 Category: Allergy & Immunology Authors: F átima Raad Paula Luque Sof ía García Ledo Alicia Alda Lozano V íctor Llorens Antonio Espejo Henar Heras Luc ía Santana Luis Trapiella Patricia Fanlo Alfredo Ad án Gerard Espinosa Nuria Navarrete Source Type: research